Vical Incorporated H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response

By Staff and Wire Reports

Tuesday, 30 June 2009 07:26

Vical Incorporated, which researches and develops biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases has announced that the Company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard 2 dose vaccine regimen.

In addition, at least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. In 2 parallel animal studies, one in mice and one in rabbits, vaccine was administered on Day 0 and Day 21, a standard regimen for pandemic influenza vaccines. Sera collected on Day 21, after a single dose of vaccine, showed clear increases over baseline hemagglutination inhibition (HI) titers in 100% of the animals, and HI titers above the protection threshold in 88% of the mice and 75% of the rabbits. Sera collected on Day 35, 2 weeks after the second dose, showed HI titers well above the protection threshold in 100% of the animals, ranging from 320 to 2,560 (geometric mean titer = 987) in the mice, and from 640 to 2,560 (geometric mean titer = 1,522) in the rabbits.

The HI assay measures a vaccine's ability to prevent viruses from binding to cells, and HI titers of 40 or more are accepted as the threshold for potential protection against influenza viruses. The vaccine encoded H1 hemagglutinin from the swine-origin A/California/04/09 wild-type influenza virus. Vical ran the HI assay against the swine-origin A/California/07/09 x-179a reassortant influenza virus obtained from the CDC.

BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites

blog comments powered by Disqus

BioMedReports

about 2 hours ago A Stem-Cell-Based Drug Gets Approval in Canada $OSIR http://t.co/XI3gAfMY

about 3 hours ago $JNJ Zytiga, a Prostate Cancer Drug, Does Well in Trial http://t.co/v7YUm9b6

about 5 hours ago $PFE Pfizer Lung Drug Stops Deadly Child Cancers in Study | http://t.co/hcfdrnCY

about 5 hours ago Human Genome Looks to Anyone but GlaxoSmithKline | http://t.co/d4IMkIn3

about 6 hours ago When David Einhorn did not mention Herbalife $HLF as a potential short candidate, that stock shot up on Wednesday | http://t.co/XpFKihQS

about 7 hours ago Stock Market: Stocks Get Hammered On Disappointing Data, Greece Worries http://t.co/FyH8zpru

about 8 hours ago Synergy Pharmaceuticals (SGYP) May Be Ready To Roll - Small Cap Stock Market Investing Tips http://t.co/FHYXlF1Q

about 10 hours ago Alvine Presents Results from Phase 2A Trial of ALV003 in Celiac Disease Patients -2012 Digestive Diseases Week Meeting http://t.co/e6Rjhbj9

Prev Next

navigation

Free Phone Trade Alerts